In this InvestorIntel interview, Tracy Weslosky talks to Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO, and Director Steve Saviuk about Valeo’s record quarterly and annual revenues for the fourth quarter and the fiscal year 2022. Having reported their best quarter ever, Steve discusses how Valeo’s story can be summed up with, “growth and more growth.”
Over the course of the interview, Steve discusses the following highlights from Valeo’s record-breaking fourth-quarter and year-end 2022 financial results:
- Record quarterly revenues of $12.7 million in FQ4-22, up 274% over FQ4-21
- Record revenues in F2022 of $27.7 million, up 105% over F2021
- Record revenues forecasted in FQ1-23
- Creation of Ophthalmology Business Unit following the addition of XIIDRA® and SIMBRINZA®, expansion of Respiratory Business Unit to include allergy following the addition of ALLERJECT®
- In excess of $60 million was raised in financings in 2022
With a sales force comprising 85 commercial representatives in the field, Steve goes on to provide an update on Valeo’s portfolio of high-growth potential products that focus on respiratory/allergy, ophthalmology, and hospital specialty products.
To access the full InvestorIntel interview, click here
Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.
About Valeo Pharma
Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory/Allergy, Ophthalmology, and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the necessary capabilities and a complete infrastructure to register and manage its growing product portfolio through all stages of commercialization.
To know more about Valeo Pharma Inc., click here
Disclaimer: Valeo Pharma Inc. is an advertorial member of InvestorIntel Corp.
This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.
This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.
Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.
If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at firstname.lastname@example.org.
Leave a Reply